In an RCT [38] published in the New England Journal of Medicine, the CR rate of newly diagnosed AML patients with IDH1/IDH2 mutation was 75.4% after receiving azacitidine combined with venetoclax, which was higher than all the studies included in our meta-analysis. This evidence concerns the gene IDH1 and acute myeloid leukemia.